Jennison Health Sciences’ vast analytical resources and thoughtful approach combine for a bold but appealing healthcare offering.
PGIM Jennison Health Sciences Z PHSZX
- NAV / 1-Day Return 50.02 / −0.87 %
- Total Assets 1.8 Bil
-
Adj. Expense Ratio
0.860%
- Expense Ratio 0.860%
- Distribution Fee Level Average
- Share Class Type Institutional
- Category Health
- Investment Style Large Growth
- Min. Initial Investment —
- Status Open
- TTM Yield —
- Turnover 64%
USD | NAV as of Jul 03, 2024 | 1-Day Return as of Jul 03, 2024, 12:32 AM GMT+0
Morningstar’s Analysis PHSZX
Will PHSZX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 53.2
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 12.90 | 226.2 Mil | Healthcare |
Merck & Co Inc | 8.31 | 145.7 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 4.84 | 84.8 Mil | Healthcare |
UnitedHealth Group Inc | 4.59 | 80.4 Mil | Healthcare |
Amgen Inc | 4.43 | 77.7 Mil | Healthcare |
Novo Nordisk A/S ADR | 4.21 | 73.7 Mil | Healthcare |
Humana Inc | 3.91 | 68.6 Mil | Healthcare |
Boston Scientific Corp | 3.50 | 61.4 Mil | Healthcare |
AstraZeneca PLC ADR | 3.31 | 58.1 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 3.22 | 56.4 Mil | Healthcare |